Therapeutic effects of paclitaxel-containing ultrasound contrast agents

Michaelann Shortencarier Tartis, Jennifer McCallan, Aaron F.H. Lum, Rachel LaBell, Susanne M. Stieger, Terry O. Matsunaga, Katherine W. Ferrara

Research output: Contribution to journalArticlepeer-review

149 Scopus citations


Drug delivery vehicles that combine ultrasonic and molecular targeting are shown to locally concentrate a drug in a region-of-interest. The drug delivery vehicles, referred to as acoustically active lipospheres (AALs), are microbubbles surrounded by a shell of oil and lipid. In a region limited to the focal area of ultrasound application, circulating AALs are deflected by radiation force to a vessel wall and can subsequently be fragmented. Ligands targeting the αvβ3 integrin are conjugated to the AAL shell and increase in vitro binding by 26.5-fold over nontargeted agents. Toxicity assays demonstrate that paclitaxel-containing AALs exert a greater antiproliferative effect after insonation than free paclitaxel at an equivalent concentration. Lastly, ultrasound and molecular targeting are combined to deliver a model drug to the endothelium and interstitium of chorioallantoic membrane vasculature in vivo. (E-mail:

Original languageEnglish (US)
Pages (from-to)1771-1780
Number of pages10
JournalUltrasound in Medicine and Biology
Issue number11
StatePublished - Nov 2006


  • Angiogenesis
  • Paclitaxel
  • Radiation force
  • Targeted drug delivery
  • Ultrasound contrast agents
  • αβ Acoustically active lipospheres (AALs)

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Biophysics
  • Acoustics and Ultrasonics


Dive into the research topics of 'Therapeutic effects of paclitaxel-containing ultrasound contrast agents'. Together they form a unique fingerprint.

Cite this